^(18)F-FDG PET/MRI在胰腺癌中的临床应用及新进展  

Clinical application and new progress of^(18)F-FDG PET/MRI in pancreatic cancer

作　　者：张在竹 周妮娜[1] 朱华[1] 杨志[1] Zhang Zaizhu;Zhou Nina;Zhu Hua;Yang Zhi(Department of Nuclear Medicine,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Key Laboratory for Research and Evaluation of Radiopharmaceuticals(National Medical Products Administration),Peking University Cancer Hospital&Institute,Beijing 100142,China)

机构地区：[1]北京大学肿瘤医院暨北京市肿瘤防治研究所核医学科,国家药监局放射性药物研究与评价重点实验室,恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142

出　　处：《国际放射医学核医学杂志》2022年第4期235-239,共5页International Journal of Radiation Medicine and Nuclear Medicine

摘　　要：胰腺癌是一种恶性程度高、易转移、进展快、预后差的恶性肿瘤,早期诊断、准确分期和及时的疗效评估对胰腺癌患者至关重要。一体化的PET/MRI作为一种新型的多模态成像技术,集合了MRI对软组织分辨率高、多序列、多参数和PET代谢显像的高灵敏度等优势,在胰腺癌患者的肿瘤分期、疗效评估、预后预测、复发监测等方面具有潜在的应用价值。因此,笔者就^(18)F-氟脱氧葡萄糖(FDG)PET/MRI的优势及其在胰腺癌中的临床应用及新进展进行综述。Pancreatic cancer is a malignant tumor with high malignant degree,easy metastasis,rapid progression and poor prognosis,so early diagnosis,accurate staging and timely efficacy evaluation are crucial for patients with pancreatic cancer.As a novel multimodality imaging technology,integrated PET/MRI combines with high resolution for soft-tissue,multi-sequences,multiparameters of MRI and high sensitivity of PET metabolic imaging,it has potential application value in tumor staging,efficacy evaluation,prognosis prediction,and recurrence monitoring of pancreatic cancer patients.Therefore,this paper reviews the advantages of^(18)F-fluorodeoxyglucose(FDG)PET/MRI and its clinical application and new progress in pancreatic cancer.

关 键 词：胰腺肿瘤 正电子发射断层显像术 磁共振成像 氟脱氧葡萄糖F18 

分 类 号：R445.2[医药卫生—影像医学与核医学] R735.9[医药卫生—诊断学] R730.44[医药卫生—临床医学]